Skip to main content
. 2020 Nov 1;10(11):3882–3895.

Table 4.

Univariate and multivariate analyses of factors associated with hepatic evens (new ascites, varices bleeding and hepatic encephalopathy) in patients with compensated cirrhosis at baseline

Variables Univariate Analysis Multivariate Analysis


Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age (year) 1.012 (0.992-1.033) 0.236
Sex, male vs. female 1.193 (0.671-2.122) 0.548
HBeAg, yes vs. no 0.861 (0.470-1.580) 0.629
NA-naïve, yes vs. no 1.895 (0.761-4.718) 0.169
TDF vs. entecavir 0.627 (0.350-1.121) 0.115
Diabetes mellitus, yes vs. no 1.509 (0.878-2.594) 0.137
Hypertension, yes vs. no 1.041 (0.611-1.775) 0.881
HBV DNA, per log10 IU/mL 0.893 (0.757-1.054) 0.180
AST, per U/L 1.000 (0.998-1.002) 0.706
ALT, per U/L 0.998 (0.995-1.001) 0.141
Total bilirubin, per mg/dL 1.057 (0.949-1.176) 0.315
Albumin, per g/L 0.265 (0.176-0.400) < 0.001 0.335 (0.217-0.517) < 0.001
INR, per ratio 1.999 (1.040-3.843) 0.038
eGFR, mL/min/1.73 m2 0.995 (0.986-1.003) 0.244
Platelet, per 103/μL 0.983 (0.978-0.989) < 0.001 0.986 (0.980-0.991) < 0.001
AFP at baseline, per ng/mL 1.001 (0.997-1.004) 0.674
Child-Pugh score 1.891 (1.550-2.308) < 0.001
FIB-4 1.086 (1.053-1.120) < 0.001
APRI 1.023 (0.972-1.076) 0.389

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.